Blinatumomab (anti-CD3&CD19) - Primary antibody, specific to CD3E; CD19, Antibody of CD19;Antibody of CD3e, Antibody of CD19;Antibody of CD3e

    Application:
  • ELISA
  • Flow Cytometry
Features and benefits
  • Host species: Human
  • Species reactivity(Reacts with): Human
  • Conjugation: Unconjugated
In stock
Item Number
Ab175475
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab175475-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$239.90
Ab175475-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,259.90

Purity≥95% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; CHO; ELISA, FACS; Unconjugated

Basic Description

Product NameBlinatumomab (anti-CD3&CD19) - Primary antibody, specific to CD3E; CD19, Antibody of CD19;Antibody of CD3e
SynonymsCD3 epsilon antibody | CD3e antibody | CD3e antigen antibody | CD3e antigen epsilon polypeptide (TiT3 complex) antibody | CD3E antigen epsilon polypeptide antibody | CD3E antigen, epsilon subunit antibody | CD3e molecule epsilon antibody | CD3e molecule,
Specifications & PurityCarrier Free, Recombinant, Low Endotoxin, Azide Free, Moligand™, Validated, ≥95%(SDS-PAGE&SEC-HPLC), See COA
Host speciesHuman
SpecificityCD3E; CD19
ConjugationUnconjugated
GradeAzide Free, Carrier Free, Low Endotoxin, Moligand™, Recombinant, Validated
Action TypeCROSS-LINKING AGENT
Mechanism of actionAntibody of CD19;Antibody of CD3e
Product Description

Blinatumomab (anti-CD3&CD19) is a bispecific monoclonal antibody which can specifically targets the CD19 antigen present on B cells. Blinatumomab (anti-CD3&CD19) can be used for the research of acute lymphoblastic leukemia.
Purity
≥95% (SDS-PAGE&SEC)
Endotoxin Level
≤1.0EU/mg

Product Properties

Light Chain Typekappa
SDS-PAGE54.05 kDa
Purification MethodNickel affinity chromatography+Molecular sieve
ShapeLiquid
ConcentrationSee COA
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS853426-35-4

Associated Targets(Human)

CD19 Tclin B-lymphocyte antigen CD19 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
CD3E Tclin T-cell surface glycoprotein CD3 epsilon chain (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
CD3E Tclin T-cell surface glycoprotein CD3 epsilon chain (0 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CD3E Tclin T cell surface glycoprotein CD3 (0 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Specifications

References

1. Mølhøj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, Kufer P, Hofmeister R, Baeuerle PA.  (2007)  CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis..  Mol Immunol,  44  (8): (1935-43).  [PMID:17083975] [10.1021/op500134e]
2. Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M, Locher M, Hammond SA, Kiener P, Kufer P et al..  (2007)  Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class..  J Immunother,  30  (8): (798-807).  [PMID:18049331] [10.1021/op500134e]
3. Aldoss I, Bargou RC, Nagorsen D, Friberg GR, Baeuerle PA, Forman SJ.  (2017)  Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors..  Leukemia,  31  (4): (777-787).  [PMID:28028314] [10.1021/op500134e]
4. Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst HA et al..  (2018)  Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia..  Blood,  131  (14): (1522-1531).  [PMID:29358182] [10.1021/op500134e]
5. Slaney CY, Wang P, Darcy PK, Kershaw MH.  (2018)  CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment..  Cancer Discov,  (8): (924-934).  [PMID:30012854] [10.1021/op500134e]

Solution Calculators

Reviews

Customer Reviews